Your browser doesn't support javascript.
loading
Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment.
Cáceres-Lavernia, Haslen Hassiul; Nenínger-Vinageras, Elia; Varona-Rodríguez, Leslie M; Olivares-Romero, Yoli A; Sánchez-Rojas, Irlis; Mazorra-Herrera, Zaima; Basanta-Bergolla, Denenke; Duvergel-Calderín, Dayanis; Torres-Cuevas, Boris L; Castillo-Carrillo, Concepción.
Afiliação
  • Cáceres-Lavernia HH; Hermanos Ameijeiras Clinical-Surgical Hospital (HHA), Havana, Cuba.
  • Nenínger-Vinageras E; Hermanos Ameijeiras Clinical-Surgical Hospital (HHA), Havana, Cuba.
  • Varona-Rodríguez LM; Hermanos Ameijeiras Clinical-Surgical Hospital (HHA), Havana, Cuba.
  • Olivares-Romero YA; Social Security and Assistance Institute, (IPASME). Caracas, Venezuela.
  • Sánchez-Rojas I; Hermanos Ameijeiras Clinical-Surgical Hospital (HHA), Havana, Cuba.
  • Mazorra-Herrera Z; Molecular Immunology Center, Havana, Cuba.
  • Basanta-Bergolla D; Hermanos Ameijeiras Clinical-Surgical Hospital (HHA), Havana, Cuba.
  • Duvergel-Calderín D; Hermanos Ameijeiras Clinical-Surgical Hospital (HHA), Havana, Cuba.
  • Torres-Cuevas BL; Hermanos Ameijeiras Clinical-Surgical Hospital (HHA), Havana, Cuba.
  • Castillo-Carrillo C; Hermanos Ameijeiras Clinical-Surgical Hospital (HHA), Havana, Cuba.
MEDICC Rev ; 23(3-4): 21-28, 2021.
Article em En | MEDLINE | ID: mdl-34516533
INTRODUCTION: Racotumomab is a therapeutic vaccine based on a monoclonal anti-idiotypic antibody developed by the Molecular Immunology Center in Havana, Cuba, that is registered in Cuba and Argentina for treatment of non-small cell lung cancer. It induces a specific humoral and cellular immune response against the N-glycolyl GM3 (NeuGcGM3) ganglioside present in tumor cells, thereby provoking the death of these cells. OBJECTIVE: Evaluate racotumomab vaccine use as switch maintenance and second-line therapy for patients with inoperable non-small cell lung cancer in routine clinical practice, outside the framework of clinical studies, and assess the overall survival, stage-specific survival and safety in these patients. METHODS: A descriptive, retrospective study was carried out in patients diagnosed with non-small cell lung cancer not suitable for surgical treatment, who received racotumomab as a part of switch maintenance or second-line treatments. Overall survival was defined from diagnosis and from the first immunization, until death. RESULTS: We included 71 patients treated with racotumomab, 57.7% (41/71) of whom were in stages IIIB and IV of non-small cell lung cancer. Of the patients, 84.5% (60/71) had no adverse events, and 15.5% (11/71) had mild adverse reactions. The median overall survival was 24.5 months, calculated from the first immunization, 17.2 months for those who received racotumomab as switch maintenance and 6.8 months for patients who had progressed after the first line of treatment. CONCLUSIONS: Racotumomab in routine clinical practice prolonged overall survival in patients with non-small cell lung cancer treated in switch maintenance, and in stage IV patients who received the treatment as second-line therapy. The vaccine was well tolerated.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Observational_studies Limite: Humans País/Região como assunto: Caribe / Cuba Idioma: En Revista: MEDICC Rev Assunto da revista: SAUDE PUBLICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Cuba País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Observational_studies Limite: Humans País/Região como assunto: Caribe / Cuba Idioma: En Revista: MEDICC Rev Assunto da revista: SAUDE PUBLICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Cuba País de publicação: Estados Unidos